Tejas Savant

Q: What is Tejas Savant's success rate?

Tejas Savant currently has a success rate of 99.80754211759456.

Q: What is the average return of Tejas Savant's calls?

Their stock ratings have generated an average return of 20.696459402469902.

Morgan Stanley | Healthcare

Tejas Savant is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #792 out of 4771 analysts, they have issued 36 stock ratings with a success rate of 99.81% and an average return of 20.70%.

Tejas Savant has a well-established track record, with 36 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 99.81% and an average return of 20.70%, underscoring their expertise and ability to identify winning opportunities for investors.

#792

Out of 4771

Total Ratings

+99.81%

Success Rate

+20.70%

Average Return

Recent Ratings Analysis

VCYT

Sell

Aug 04, 2026

Target

$44.00

Current

$42.03

Performance

-9.44%

Tejas Savant rated VCYT as Underweight on Aug 04, 2026, setting a price target of 44. The Sell call didn’t play out, with shares rallying -9.44% to 42.03.

AVTR

Hold

Jul 30, 2026

Target

$14.00

Current

$14.88

Performance

7.36%

On Jul 30, 2026, AVTR was given a Equal-Weight rating by Tejas Savant, with a target price of 14. The stock rallied from 14.88 to 14.88 after the Hold rating, surprising to the upside.

ADPT

Hold

Jul 30, 2026

Target

$22.00

Current

$24.23

Performance

0.21%

ADPT received a Equal-Weight rating from Tejas Savant on Jul 30, 2026, aiming for 22. Shares remained flat at 24.23, aligning with the neutral rating.

TMO

Buy

Jul 27, 2026

Target

$650.00

Current

$603.18

Performance

7.80%

On Jul 27, 2026, Tejas Savant published a Overweight outlook on TMO, with a target of 650. Shares gained 7.80%, underscoring the accuracy of the bullish outlook toward 650.

NTRA

Buy

Jul 09, 2026

Target

$310.00

Current

$326.14

Performance

15.71%

Tejas Savant on Jul 09, 2026 assigned NTRA a Overweight rating, with a price target of 310. The Buy call aligned well with market performance, producing a gain of 15.71%.

TXG

Hold

Jul 09, 2026

Target

$37.00

Current

$66.38

Performance

54.01%

On Jul 09, 2026, Tejas Savant reaffirmed TXG with a Equal-Weight rating, targeting 37. Market strength beyond 66.38 went further than the conservative outlook suggested.

PSNL

Hold

Jul 09, 2026

Target

$13.00

Current

$16.33

Performance

11.47%

PSNL was rated Equal-Weight by Tejas Savant on Jul 09, 2026, with a price objective of 13. Despite caution, upside momentum rewarded risk-takers with gains to 16.33.

CTKB

Hold

May 12, 2026

Target

$5.50

Current

$4.53

Performance

12.13%

On May 12, 2026, Tejas Savant initiated coverage on CTKB with a Equal-Weight rating and target of 5.5. The Hold stance underestimated the stock’s strength as it gained 12.13%.

STVN

Hold

Mar 06, 2026

Target

$24.00

Current

$20.95

Performance

35.95%

Tejas Savant issued a Equal-Weight recommendation for STVN on Mar 06, 2026, price target set at 24. A neutral call gave way to stronger-than-expected performance, closing in on 24.

TEM

Buy

Mar 03, 2026

Target

$85.00

Current

$58.74

Performance

14.28%

On Mar 03, 2026, TEM was evaluated by Tejas Savant, who gave a Overweight rating and target of 85. This case illustrates how a timely bullish rating can translate into tangible gains of 14.28%.

GRAL

Hold

Feb 24, 2026

Target

$110.00

Current

$77.56

Performance

54.04%

Tejas Savant rated GRAL as Equal-Weight on Feb 24, 2026, setting a price target of 110. Despite the Hold call, shares climbed 54.04% to 77.56, revealing unexpected momentum.

IQV

Buy

Dec 02, 2025

Target

$265.00

Current

$257.30

Performance

14.04%

On Dec 02, 2025, IQV was given a Overweight rating by Tejas Savant, with a target price of 265. The stock rallied 14.04% after the rating, narrowing the gap to the target of 265 and validating the bullish stance.

HOLX

Hold

Nov 11, 2025

Target

$76.00

Current

$76.01

Performance

1.89%

HOLX received a Equal-Weight rating from Tejas Savant on Nov 11, 2025, aiming for 76. Shares remained flat at 76.01, aligning with the neutral rating.

ILMN

Hold

Aug 04, 2025

Target

$105.00

Current

$201.27

Performance

104.46%

On Aug 04, 2025, Tejas Savant published a Equal-Weight outlook on ILMN, with a target of 105. The Hold call missed some of the bullish momentum as shares advanced toward 105.

NEO

Hold

Jul 30, 2025

Target

$8.00

Current

$17.61

Performance

245.29%

Tejas Savant on Jul 30, 2025 assigned NEO a Equal-Weight rating, with a price target of 8. Shares outperformed expectations, climbing 245.29% despite the neutral view.

MRVI

Hold

Mar 25, 2025

Target

$5.00

Current

$6.73

Performance

192.61%

On Mar 25, 2025, Tejas Savant reaffirmed MRVI with a Equal-Weight rating, targeting 5. Market strength beyond 6.73 went further than the conservative outlook suggested.

MYGN

Hold

Nov 18, 2024

Target

$21.00

Current

$3.36

Performance

-77.92%

MYGN was rated Equal-Weight by Tejas Savant on Nov 18, 2024, with a price objective of 21. Investors who stayed cautious avoided some of the 77.92% decline.

Frequency Asked Questions

Who is Tejas Savant?

Tejas Savant is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Tejas Savant's success rate?

Tejas Savant currently has a success rate of +99.81%.

How many ratings has Tejas Savant issued?

Tejas Savant has issued 36 stock ratings so far.

What is the average return of Tejas Savant's calls?

Their stock ratings have generated an average return of +20.70%.

What is Tejas Savant's ranking?

Tejas Savant is ranked #792 out of 4771 analysts.

What types of ratings does Tejas Savant give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Tejas Savant?

You can follow Tejas Savant by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Tejas Savant?

Their latest rating was a Sell on VCYT issued on 2026-08-04.